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ABSTRACT   
Ewing sarcoma is characterized by chromosomal translocations fusing the EWS gene with various 
members of the ETS family of transcription factors, most commonly FLI1. EWSFLI1 is an aberrant 
transcription factor driving Ewing sarcoma tumorigenesis by either transcriptionally inducing or 
repressing specific target genes. Herein, we showed that Sprouty 1 (SPRY1), which is a physiological 
negative feedback inhibitor downstream of fibroblast growth factor (FGF) receptors (FGFRs) and 
other RAS-activating receptors, is an  
EWS-FLI1 repressed gene. EWS-FLI1 knock-down specifically increased the expression of SPRY1 
while other Sprouty family members remained unaffected. Analysis of SPRY1 expression in a panel 
of Ewing sarcoma cells showed that SPRY1 was not expressed in Ewing sarcoma cell lines, suggesting 
that it could act as a tumor suppressor gene in these cells. In agreement, induction of SPRY1 in three 
different Ewing sarcoma cell lines functionally impaired proliferation, clonogenic growth and 
migration. In addition, SPRY1 expression inhibited ERK/MAPK signalling induced by serum and basic 
FGF (bFGF). Moreover, treatment of Ewing sarcoma cells with the potent FGFR inhibitor PD-173074 
reduced bFGF-induced proliferation, colony formation and in vivo tumor growth in a dosedependent 
manner, thus mimicking SPRY1 activity in Ewing sarcoma cells. Although the expression of SPRY1 
was low when compared to other tumors, SPRY1 was variably expressed in primary Ewing sarcoma 
tumors and higher expression levels were significantly associated with improved outcome in a large 
patient cohort. Taken together, our data indicate that EWS-FLI1-mediated repression of SPRY1 leads 
to unrestrained bFGF-induced cell proliferation, suggesting that targeting the FGFR/MAPK pathway 
can constitute a promising therapeutic approach for this devastating disease.   
Keywords  
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Ewing sarcomas are aggressive bone and soft-tissue sarcomas mostly affecting children and young 
adults 1. Although the 5-year survival in patients with localized disease increased significantly upon 
the addition of systemic chemotherapy to protocol treatments in the 70s80s 2, the prognosis and 
survival of patients with metastatic or recurrent disease remained generally very poor 3. Indeed, 
Ewing sarcoma features high rates of early metastasis with about 20% of patients having detectable 
metastases at diagnosis 4.   
The molecular hallmarks of Ewing sarcoma are nonrandom chromosomal translocations generating 
in-frame fusion of the EWS gene on chromosome 22 and the carboxyl terminus of a member of the 
ETS family of transcription factors (i.e. FLI1, ERG, ETV1, FEV, ETV4, POU5F1) including the DNA-
binding domain 5 (reviewed in 1). This fusion gives rise to aberrant EWS-ETS transcription factors, 




EWS-FLI1 induces massive deregulation of protein expression by either transcriptionally inducing or 
repressing specific target genes, many of which are involved in the oncogenic process 6. For instance, 
EWS-FLI1 induces the expression of NR0B1 (DAX1), EGR2, NKX2.2, CCK, PRKCB or STEAP1 7 8 9 
10 11, while suppressing IGFBP3, LOX, DKK1 or TGFBIIR 12 13 14 15. All these genes have been shown 
to be important in Ewing sarcoma pathogenesis.   
Here, we report on the tumor suppressive role of another repressed EWS-FLI1-targetd gene, namely 
Sprouty 1 (SPRY1), which is a negative feedback inhibitor of the  
RAS/MAPK/ERK pathway downstream of the FGF receptor (FGFR).  
SPRY1 is part of the mammalian Sprouty gene family consisting of four members (SPRY1 to 4), which 
share important sequence similarities 16 such as a highly conserved cysteinerich domain in the C-
terminal region (which is also found in the SPRED family of proteins) and a short amino acid 
sequence in the N-terminus 17. SPRY proteins differ largely in their tissue distribution, activity and 
interaction partners 18, thus suggesting non-redundant functions. SPRY1 is an upstream antagonist 
of RAS that is activated by extracellular signal-related kinase (ERK), providing a negative feedback 
loop for RAS signaling. Of note, about one third of all human cancers are thought to carry a mutated 
RAS gene that activates downstream signaling19. It has been suggested that SPRY1 may have a tumor 
suppressor function in specific tumors since its expression is decreased in several human cancers 
such as breast and prostate cancer 20 21 22. Indeed, several studies showed that SPRY1 overexpression 
in tumor cell lines inhibits cell proliferation, migration and anchorage-independent growth in vitro 
23 21 24.   
In this study, we show that SPRY1 acts as a tumor suppressor in Ewing sarcoma cells, and that SPRY1 
repression is necessary for cell proliferation and migration. Interestingly, SPRY1 repression was 
important to ERK pathway activation. Moreover, FGFR-inhibition mimicked SPRY1 effect on 
proliferation and growth, indicating that SPRY1 plays an important role in Ewing sarcoma. Finally, 
elevated SPRY1 expression correlated with improved overall survival of Ewing sarcoma patients and 
inversely correlated with metastasis at diagnosis. Collectively, our data indicate that EWS-FLI1-
mediated repression of SPRY1 confers a growth advantage to Ewing sarcoma cells and that SPRY1 
levels constitute a novel biomarker for outcome prediction of Ewing sarcoma patients. Taken 
together these results suggest a rationale for targeting FGFR/SPRY1/RAS/MAPK/ERK pathway as a 
new therapeutic approach in this devastating disease.   
RESULTS  
  
SPRY1 expression is strongly inhibited by EWS-FLI1 in Ewing sarcoma cell lines  
Analysis of a gene expression profile of A673 Ewing sarcoma cell line genetically modified to express 




(Gene Expression Omnibus (GEO) accession code: GSE36007), indicated that SPRY1 is strongly 
down-regulated by EWS-FLI1. These microarray results were confirmed by RT-qPCR experiments. As 
depicted in Figure 1A, EWS-FLI1 knockdown led to a dramatic re-expression of SPRY1 mRNA (up to 
1,000-fold compared to controls), while the mRNA levels of the other members of the SPRY family  
(SPRY2, 3 and 4) were only minimally affected. Analysis of SPRY1 protein levels in the A673/TR/shEF 
cell model confirmed these results. As shown in Figure 1B, SPRY1 protein was undetectable by 
western blot in A673/TR/shEF grown in absence of doxycycline. However, a strong induction of 
SPRY1 protein was observed upon doxycycline-mediated EWS-FLI1 knockdown.   
We next studied whether the inhibition of SPRY1 expression could be a common feature of Ewing 
sarcoma cells. We first analyzed the levels of SPRY1 mRNA and protein in a panel of eight Ewing 
sarcoma cell lines harboring different EWS-FLI1 or EWS-ERG fusion proteins (Supplementary Table 
1). As shown in Figure 1C and 1D, SPRY1 mRNA and protein were undetectable in all Ewing sarcoma 
cell lines analyzed. Interestingly, the mRNA levels of the other members of the SPRY family were 
variably expressed in this panel of Ewing sarcoma cells. These data could also be confirmed assessing 
larger public datasets. For instance, analysis of Cancer Cell Line Encyclopedia dataset 25 
(http://www.broadinstitute.org/ccle/home) showed that Ewing sarcoma cell lines exhibited the 
lowest SPRY1 levels amongst all tumor cell lines analyzed (Supplementary Figure 1).  
SPRY1 induction impairs cell proliferation of Ewing sarcoma cells  
The strong down-regulation of SPRY1 by EWS-FLI1, its absence of expression in Ewing sarcoma cell 
lines and the finding that it acts as a negative feedback inhibitor of the RAS/MAPK/ERK cascade 
suggest a potential function of SPRY1 inhibition in Ewing sarcoma. To test this hypothesis, we 
generated three doxycycline-inducible SPRY1 Ewing sarcoma cell lines (A673/TR/SPRY1, 
SKES/TR/SPRY1, and SKNMC/TR/SPRY1) and subjected them to several functional assays. As shown 
in Figure 2A, these genetically modified Ewing cell lines express high levels of SPRY1 protein upon 
doxycycline stimulation, while the levels of the EWS-FLI1 oncoprotein remain unaffected. Thus, they 
constitute a suitable model to test the consequences of exclusive SPRY1 re-expression in Ewing 
sarcoma without affecting the levels of EWS-FLI1 oncoprotein.  
Firstly, we studied the effect of SPRY1 induction on cell proliferation (Figures 2B-D). Induction of 
SPRY1 in these Ewing cell lines upon doxycycline stimulation significantly reduced their proliferation. 
This was observed using real-time monitoring of cell number (xCELLigence instrument, ACEA 
Biosciences) (Figure 2B) as well as by  
bromodeoxyuridine (BrdU) incorporation assays (Figures 2C and 2D). Notably, no effect on cell 
proliferation was observed in cells carrying the empty vector, both in absence and in presence of 
doxycycline (data not shown). Cell proliferation inhibition was observed in standard culture media 




2D). Induction of SPRY1 in cells grown in lowserum conditions exhibited an even stronger reduction 
of cell proliferation (Figure 2D), probably suggesting that in conditions where there is a diminished 
availability of growth factors, such as in the tumor microenvironment, SPRY1 is able to markedly 
impair cell proliferation.  
Similarly, induction of SPRY1 expression reduced clonogenic growth of the three Ewing sarcoma cell 
lines plated at very low density in medium supplemented with 5% FBS whereas cells carrying the 
empty vector remained unaffected upon doxycycline treatment (Figure 3A, Supplementary Figure 
2A). When cells were tested for anchorage-independent growth in soft agar, no significant 
differences were observed in the number of colonies formed, whereas there was a significant 
difference in the size of the individual colonies (Figure 3B). No significant differences in anchorage-
independent growth were observed in cells transfected with the empty vector when treated 
accordingly (Supplementary Figure 2B).   
Finally, the three Ewing cell lines harboring the SPRY1 construct where cultured in presence or 
absence of doxycycline and assayed for cell cycle in non-synchronized cells by flow cytometry. As 
shown in Supplementary Figure S3, the impairment in cell proliferation in SPRY1-re-expressing cells 
seems partially due to a cell cycle arrest in the G1 phase, although these results were not statistically 
significant.    
Taken together, these results provide evidence that SPRY1 induction impairs cell proliferation as 
well as clonogenic and anchorage-independent growth of Ewing sarcoma  
cell lines.  
  
  
SPRY1 induction impairs migration of Ewing sarcoma cells  
We next analyzed the effect of SPRY1 induction in Ewing sarcoma cells on cell migration.  
As shown in Figure 3C, SPRY1 induction reduced the ability of A673, SKES, and SKNMC Ewing 
sarcoma cells to close an artificial wound produced in a confluent cell monolayer (in vitro wound 
healing assay). In addition, SPRY1 re-expression significantly impaired migration of Ewing sarcoma 
cells through a porous membrane (transwell assay) (Figure 3D). No differences in the migratory 




SPRY1 repression is necessary for ERK activation and proliferation in Ewing  
sarcoma cells.   
SPRY1 has been described to inhibit MAPK/ERK pathway, which is one of the most relevant 
proliferative pathways in cancer. For that reason we investigated the effect of SPRY1 induction on 
ERK activation mediated by serum. As shown in Figure 4, SPRY1 induction reduced the levels of 
phospho-ERK both in low (1%) and standard (10%) serum conditions. Next, we explored the effect 
of SPRY1 induction on the ERK activation mediated by bFGF, an established and potent RAS-
activating growth factor. Using bFGFstimulation we observed a similar effect on ERK activation 
(Figure 4) in the three Ewing  
cell lines.   
Collectively, these results indicate that EWS-FLI1-mediated SPRY1 repression in Ewing sarcoma cells 
contributes to the activation of MAPK/ERK pathway, and thus to the malignant features observed.  
  
FGFR-inhibitors mimic the effects of SPRY1 re-expression.  
Since SPRY1 proved to be capable of inhibiting ERK phosphorylation, especially when the  
FGF pathway was activated, we assessed the effect of 4 FGFR-inhibitors (PD-173074 [PD74], PD-
166866 [PD-66], SU5402 [SU54] and NVP-BGJ398 [BG-98]) on Ewing sarcoma cells (A673, SKNMC, 
SKES, RDES and POE) in order to test whether FGFR-inhibition can mimic SPRY1 effect on Ewing cell 
lines. Complementarly to our previous finding that bFGF can induce proliferation in Ewing sarcoma 
cell lines (i.e. A673, SKNMC  and POE cells) 26, we observed that FGFR-inhibition reduces proliferation 
of these Ewing sarcoma cells (Figure 5A) whereas it did not affect normal cells such as fibroblasts 
(IMR90). Consistently, FGFR-inhibition through any of the 4 FGF-inhibitors severely impairs 
clonogenic growth of A673, SKNMC and POE Ewing sarcoma cell lines (Figure 5B).   
Since POE cells exhibited high sensitivity toward this FGFR inhibiton compared to the other cells 
tested (Supplementary Table 2), we chose this cell line to perform in vivo experiments to test 
whether PD-74 has an antitumoral effect in a xenograft model in mice. As shown in Figure 5C, PD-
74 treatment significantly inhibited tumor growth (P = 0.004) of Ewing sarcoma xenografts. These 




increase in the number of apoptotic cells per highpower field (P = 0.001) when comparing vehicle 
vs. PD-74 treatment. Moreover, Ki-67 staining for proliferation showed a significant reduction in the 
number of Ki67-positive cells in the tumor samples treated with PD-74 (P < 0.01) (Figure 5D).   
To confirm if PD-74 had an antitumoral effect in other Ewing sarcoma cell lines we performed an in 
vivo experiment using SKES cells, which presented less sensitivity to it in vitro (Figure 5A). As shown 
in Supplementary Figure S4A, PD-74 had a dose-dependent effect on SKES xenograft growth in mice, 
with 20 mg/kg being the most effective dose (P = 0.005). Again we observed a significant reduction 
of the number of mitoses (P = 0.01) and a significant increase in the number of apoptotic cells per 
high-power field (P < 0.001) upon treatment with PD-74 (20 mg/kg) (Supplementary Figure S4B). 
Similarly, we detected significantly less Ki-67 positive cells upon treatment of with PD-74 (P < 0.01) 
(Supplementary Figure S4B).   
We next explored the combined effect of FGFR-inhibition and SPRY1 re-expression. SPRY1 was re-
expressed in the three Ewing sarcoma cell lines and they were concomitantly treated with either 
bFGF or PD-74 alone or a combination of both (Figure 6). In analogy to the results presented in Figure 
2, SPRY1 significantly inhibited cell proliferation induced by bFGF in the three cell lines studied. 
Moreover, the effect of SPRY1 re-expression and PD-74 on cell proliferation was similar in A673 and 
SKNMC cells (Figure 6). Furthermore, when the three cell lines were treated with other FGFinhibitors 
(BG98, PD-66 and SU54) two of them (BG98 and PD-66) were able to significantly further reduce the 
proliferation beyond the effect of SPRY1 alone (Supplementary Figure S5). However, when SPRY1 
was re-expressed concomitantly with any of the three new inhibitors tested, none of them produced 
a further impairment in proliferation on any of the cells tested, which is in agreement with what was 






SPRY1 expression positively correlates with improved overall survival of Ewing sarcoma 
patients.   
Our results indicate that SPRY1 repression leads to a constitutive activation of MAPK/ERK pathway 
in response to external stimuli such as bFGF. Thus, we wondered if the expression levels of SPRY1 in 
situ could be associated with clinical outcome in Ewing sarcoma patients.   
First, SPRY1 mRNA levels were examined in a cohort of 117 Ewing sarcoma samples studied with 
gene expression microarrays and compared them to published microarray datasets comprising 24 
different solid tumor types27. This analysis revealed that Ewing sarcoma range among the ones with 
the lowest SPRY1 expression (Figure 7A), although in in situ tumors there was more heterogeneity 
in the SPRY1 mRNA levels as compared to Ewing sarcoma cells in culture (Figures 7B). Moreover, 
there was statistically less SPRY1 expression in Ewing sarcoma cell lines as compared to primary 
tumors. In fact, all cell lines except for one exhibited less SPRY1 expression than the median sample 
of primary tumors. In contrast, there was no statistical difference in LOX, NR0B1 and CD99 
expression in cell lines when compared to primary tumors (Figure 7B).  
Then, we analyzed the correlation between SPRY1 levels in primary tumors and clinical outcome in 
a cohort of 162 Ewing sarcoma patients28. The median expression value of SPRY1 was used as a cut-
off to define moderate and low SPRY1 expression levels. Using this cut-off, moderate SPRY1 
expression levels were significantly associated with a better overall survival (5-year overall survival 
0.70 vs 0.38, P = 0.002; log-rank test) and event free survival (5-year event free survival 0.72 vs 0.45, 
P = 0.0015; log-rank test) (Figures 7C and D). Interestingly, low SPRY1 levels were associated with a 
higher risk for the presence of metastases at diagnosis (P = 0.002, Fisher’s exact test) (Figure 6E). 
Collectively, these results strongly support a relationship between the levels of SPRY1 and Ewing 
sarcoma aggressiveness.  





EWS-ETS fusion proteins play a central role in the pathogenesis of Ewing sarcoma by regulating the 
expression of other key players. In this sense, the identification of these regulated genes may help 
characterize the pathways involved in Ewing sarcoma pathogenesis and aggressiveness and to 
therefore open new opportunities for targeted  
therapies 29.  
In this study, we showed that SPRY1, a member of the Sprouty family of proteins, is  repressed by 
EWS-FLI1 and is not expressed in established Ewing sarcoma cell lines. The exact mechanism through 
which EWS-FLI1 regulates SPRY1 is still unknown. However, analysis of two independent ChIP-Seq 
studies 30, 31 indicates that EWS-FLI1 does not bind to SPRY1 promoter directly (Supplementary 
Figure S6). Interestingly, upon EWS-FLI1 knockdown there is an increase of H3K27ac marks located 
at the putative SPRY1 promoter comprising SPRY1 exon 1 and intron 1 (Supplementary Figure S6). 
This suggests an epigenetic mechanism of SPRY1-regulation involving histone modifications, 
instead of a direct binding of EWS-FLI1 to the SPRY1 promoter. Moreover, there were no significant 
difference in the percentage of SPRY1 CpG islands’ methylation upon modulation of EWS-FLI1 
expression levels32. Accordingly, we propose that the actual mechanism underlying SPRY1 
regulation in Ewing sarcoma may be different from the one operating in other tumors where SPRY1 
downregulation is associated with promoter methylation22, 33, 34.   
Since SPRY1 has been shown to be a potent negative regulator of the RAS/MAPK/ERK signaling 
pathway 35, we hypothesized that SPRY1 may act as a tumor suppressor gene in  
Ewing sarcoma. In support of this notion, induction of SPRY1 in three independent Ewing sarcoma 
cell lines significantly impaired cell proliferation and migration. This is consistent with a tumor 
supressor function of SPRY1 in Ewing sarcoma and in agreement with previous reports showing that 
SPRY1 overexpression impairs cell growth, proliferation, migration and invasion of a variety of 




cancer, lung adenocarcinoma, colon carcinoma or osteosarcoma 24, 36-38.  
Our results also demonstrate that SPRY1 downregulation is necessary for bFGF-mediated 
proliferation and activation of RAS/MAPK/ERK pathways in Ewing sarcoma cells. Thus, SPRY1 re-
expression in the three Ewing sarcoma cell lines used in this study impaired cell proliferation and 
ERK phosphorylation induced by bFGF. bFGF is known to mediate proliferation, migration and 
differentiation in various cellular contexts 39-42 and FGFregulated pathways play a preponderant role 
in cancer (reviewed in 43). Notably, an important role for FGF-dependent pathways in Ewing sarcoma 
pathogenesis is emerging. We have recently reported that bFGF increases proliferation of Ewing 
sarcoma cells in vitro and that EGR2, which is a downstream component of the FGF pathway, is an 
EWSFLI1 induced target gene 26. Other studies have demonstrated that bFGF regulates motility and 
invasion of Ewing sarcoma cells in the bone microenvironment 44. In agreement, Agelopoulos et al. 
recently showed that constitutive knockdown of FGFR1 abolishes engraftment of Ewing sarcoma 
xenografts in mice45. Interestingly, over 75% of Ewing sarcoma biopsy samples present moderate-
to-high levels of FGFR1 phosphorylation 44, although activating FGFR1 mutations are extremely rare 
in this disease 45.  
In light of these facts and our new results, we propose that constitutive activation of FGFRs and 
downstream pathways are key contributors to the pathogenesis of Ewing sarcoma and that EWS-
FLI1-mediated suppression of the negative-feedback regulator SPRY1 constitutes a major 
mechanism for sustained FGFR-phosphorylation and thus unrestrained FGF-induced signal 
transduction and tumor progression. In synopsis, our results support that SPRY1 downregulation is 
pre-requisite for enhanced proliferation and migration of Ewing sarcoma cells induced by either 
EWS-FLI1 itself, external growth factor stimulation, or a combination of both as part of an autocrine 
loop.   
The importance of this pathway in Ewing sarcoma pathogenesis is additionally illustrated by FGFR-
inhibition-mediated impairment of cell proliferation and clonogenic growth of Ewing sarcoma cells 
in vitro. Interestingly, the search for more efficient and specific FGFR inhibitors is an active field in 
the pharmaceutical industry, since FGF signaling pathways is one of the most commonly mutated 
systems in cancer 43. In this regard, the Ewing sarcoma research community can take advantage of 
the development of these new drugs, some of which are being tested in clinical trials with promising 
results, particularly in tumors harboring aberrant FGFR signaling (reviewed in 43).   
FGFR signaling can be aberrantly activated in Ewing sarcoma either through downregulation of 
SPRY1 (as observed in most cases), through overexpression of FGFRs (as observed in subset of 
patients45) or, very rarely through somatic mutations45. For that reason, we anticipate that Ewing 




In support of this notion, Agelopoulus et al. reported on a single patient affected by relapsed Ewing 
sarcoma, who was treated with an FGFR-tyrosine kinase inhibitor (ponatinib), which led to a 
reduction in 18-FDG-PET activity and thus glucose uptake by the tumor45.  
Interestingly, although SPRY1 was undetectable in established Ewing sarcoma cell lines, its levels in 
primary tumors were variable. Currently, the reasons for the differences between SPRY1 levels in 
established cell lines and tumors in situ are still unknown but it can be hypothesized that SPRY1 
levels remain variable in tumors, and that the harsh conditions of in vitro cell culture favor the 
growth of cells with lower SPRY1 levels during establishment of Ewing sarcoma cell lines. In fact, 
established Ewing sarcoma cell lines harbor a much higher rate of STAG2, TP53 and CDKN1A 
mutations than the observed in primary tumors specimens 46, suggesting that cells derived from 
more aggressive tumors are favored in culture 47 48.   
Ewing sarcoma is a very aggressive pediatric malignancy in which primary metastasis is the most 
unfavorable risk factor, very often leading to fatal outcome despite highly intense and toxic 
treatment 49. Here, we show that low SPRY1 expression levels correlate with a significantly worse 
overall and event-free survival in a large cohort of Ewing sarcoma patients. More interestingly, 
primary tumors displaying low levels of SPRY1 were more frequently observed in patients harboring 
metastasis at diagnosis. This is compatible with a more aggressive behavior of SPRY1-low tumors 
and in agreement with the results observed in the in vitro experiments. We speculate that tumors 
expressing low levels of SPRY1 would present a higher response to external growth factor 
stimulation, and thus exhibit higher rates of proliferation and migration, making them more 
aggressive. This may have a potential clinical application since SPRY1 has been recently proposed as 
a possible tissue biomarker to differentiate aggressive from indolent prostate carcinomas 50.   
In summary, our data provide evidence that EWS-FLI1-mediated SPRY1 downregulation is an 
important mechanism in Ewing sarcoma pathogenesis. Moreover, our results strongly suggest that 
bFGF-mediated stimulation of cell proliferation could be more important than initially 
acknowledged in Ewing sarcoma and that FGFR inhibitors may constitute promising drugs for 
treatment of Ewing sarcoma patients.  
 
  
MATERIAL AND METHODS  
Cell culture  
A673/TR/shEF cells, which have been described elsewhere 7 were cultured in Dulbecco’s modified 




Clontech, Mountain View, CA), 2 mM L-glutamine, 100 µg/ml zeocin and 3 µg/ml blasticidin. 
Induction of a small hairpin RNA (shRNA) against EWS-FLI1 was started by the addition of 1 µg/ml 
doxycycline (Sigma, St Louis, MO). Ewing sarcoma cell lines A4573, TC-71, RD-ES, POE, TTC-466 and 
the normal fibroblast cell line IMR90 were maintained in RPMI 1640 medium; SK-PN-DW and SKNMC 
wildtype cells in  
Iscove’s modified Dulbecco’s medium; wildtype A673 and SKES cells in DMEM. All media were 
supplemented, if not otherwise stated, with 10% FBS, 2 mM L-glutamine (Invitrogen, Paisley, UK) 
and 1% penicillin and streptomycin. All cells were routinely tested for mycoplasma contamination 
(Mycoalert mycoplasma detection kit, Lonza # LT07318) and were authenticated by STR profiling at 
the Genomic Facility at Biomedical Research Institute, CSIC, Madrid, Spain).  
Establishment of Ewing sarcoma cell lines stably expressing doxycycline-inducible 
SPRY1 cDNA  
The complete coding region of SPRY1 was RT-PCR-amplified from A673/TR/shEF cells  
stimulated with doxycycline using primers 5’GCGGTCGACGAGATCACTACACATGGATCC-3’ (forward) 
and 5’- 
CGGCGGCCGCTCATCATCATGATGGTTTACCCTGACC-3’ (reverse); The amplified fragments were 
digested with SalI and NotI, cloned into the pENTR2B plasmid  
(Invitrogen) and transferred by recombination to the lentiviral doxycycline-inducible plasmid 
pLenti4-TO-V5-DEST (Invitrogen). Then, A673/TR, SKES/TR and SKNMC/TR Ewing sarcoma cells 
expressing the tetracycline repressor constitutively were infected with lentiviruses containing the 
SPRY1 cDNA. Control cells were infected with empty lentiviral vector. Stable clones were selected 
with zeocin (100 µg/ml). Induction of SPRY1 was assayed by western blots upon doxycycline (1 
µg/ml) stimulation. Clones displaying the highest levels of protein expression upon doxycycline 
stimulation were chosen for additional studies.  
Reverse transcription–quantitative polymerase chain reaction (RT-qPCR)  
RT-qPCR conditions, primer and TaqMan probe sequences specific for EWS-FLI1, LOX, 
NR0B1(DAX1) and TBP were described elsewhere 7, 13, 51. TaqMan probes for SPRY1, 2, 3 and 4 were 
purchased to Life Technologies (San Diego, California, USA). Reactions were run on a RotorGene 
6000 (Corbett Research, Sydney, Australia) and relative expression was calculated as previously 




Western blot analysis and antibodies  
Procedure was described elsewhere 13. Primary antibodies were purchased to the following 
companies: anti-FLI1 polyclonal antibody from NeoMarkers (# RB-9295-P) (Fremont, CA), anti-SPRY1 
monoclonal antibody from Santa Cruz Biotechnology (#100861) (Texas, USA), Tubulin monoclonal 
antibody from Sigma Aldrich (#T9026) (St. Louis, MO, USA), anti-Phospho-p44/42 (pERK, #9106) and 
anti-p44/42 (totalERK, # 9102) were from Cell Signaling (Danvers, MA, USA). Anti-mouse (# 2055) and 
anti-rabbit IgG (# 2054) horseradish peroxidase-conjugated secondary antibodies were purchased 
from Santa Cruz Biotechnology.   
  
  
BrdU proliferation assay  
Cells were plated in octaplicates (1x103 cells per well in 96 multi-well plates) and cultured in 
presence or absence of doxycycline (1 µg/ml) for 72 h in 10% or 1% tetracycline-free  
FBS (Clontech, Mountain View, CA, USA). Thereafter, BrdU chemiluminescent assay  
(Roche, Basel, Switzerland) was performed according to manufacturer’s instructions.  
Chemiluminescence was measured using an Infinite M200 (Tecan, Mannerdorf,  
Switzerland) microplate reader.   
Resazurin proliferation assay  
Cells were plated in octaplicates (2.5x103 cells per well in 96 multi-well plates) and concomitantly 
cultured in presence or absence of doxycycline (1 µg/ml) and stimuli (1% or 10% tetracycline-free 
FBS or 10 ng/ml bFGF) for 72 hours. For bFGF-inhibitor testing, cells were grown at 10% FBS for 72 
hours in presence of PD-173074 (PD-74)  
(Selleckchem, Houston, TX, USA), PD-166866 (PD-66) (#PZ0114, Sigma Aldrich),  
SU5402 (SU54) (#S7667, Selleckchem, Houston, TX, USA) or NVP-BGJ398 (BG-98)  
(#S2183, Selleckchem, Houston, TX, USA). Thereafter, Resazurin (#R7017, Sigma Aldrich) was added 
to the media at 0.15µg/ml and incubated for 2 hours at 37ºC. Fluorescence was recorded using a 
560 nm excitation/590 nm emission filter set in an  




xCELLigence proliferation assay   
Cell proliferation was assayed in real-time with a bioelectric xCELLigence instrument (Roche/ACEA 
Biosciences, San Diego, CA). In each well, 3-4x103 Ewing sarcoma cells were seeded in 200 µl media 
containing 10% tetracycline-free FBS and treated with doxycycline (1 µg/ml) or vehicle (triplicate 
wells/group). Cellular impedance was measured periodically and media with or without doxycycline 
were changed once after 72 h.   
Flow cytometry analysis of cell cycle   
Cells were treated with doxycycline (1 µg/ml) for 72 h to induce the expression of SPRY1 and fixed 
with 70% ethanol for 24 hours at 4 ºC. Then they were stained with a solution of 0.005% (w/v) of 
propidium iodide (PI) and RNAase A as recommended by the manufacturer (BD biosciences, San 
José, CA, USA) and were incubated at 37 ºC for 30 minutes. They were then analyzed in a MACS 
Quant Analyzer flow cytometer (Miltenyi  
Biotec, Cologne, Germany).   
Wound healing assay  
Cells were plated in triplicates (2-4x104 cells per well in 24 multi-well plates) and were incubated 
with or without doxycycline (1 µg/ml) for 72 h prior to the assay. At the end of this period, a “wound 
gap” in the cell monolayer was created using a micropipette tip. The healing of the gap by cell 
migrating was monitored by photographing the progress every 6 to 12 h until wound closure. 
Quantification of relative cell migration is described elsewhere  
52.   
Transwell assay   
Cells were pre-treated with doxycycline (1 µg/ml) for 24 h to induce the expression of SPRY1 protein. 
Then, they were starved (0.5% fetal bovine serum) for another additional 24 hours in the same 
doxycycline conditions. Then, 3x105 pre-treated cells were resuspended in 2 ml of medium 
containing 0.5% tetracycline-free FBS and placed in the upper chamber of transwells (8.0 µm pore 






Soft agar assays  
Cells were plated by triplicate (5x105 cells per 60 mm dishes) in soft agar and cultured in presence 
or absence of doxycycline during 25 days. Fresh culture medium was added to plates every 2–3 days. 
At the end of the experiment, three random fields for each plate were photographed. The number 
of colonies per field and its respective area were calculated using NIH ImageJ software.   
Clonogenic assay  
A673/TR/SPRY1, SKES/TR/SPRY1 and SKNMC/TR/SPRY1 cells were plated in  
triplicates at 0.5x103, 1x103 and 2x103 cells per well respectively in a 24-well plate. They were 
subsequently treated with or without doxycycline (1 µg/ml) and maintained for 9 days in culture 
media supplemented with 5% tetracycline-free FBS. Media was changed every 34 days and 
doxycycline treatment was continued. Finally, colonies were fixed, stained with crystal violet and 
photographed. Cells were de-stained using 50% ethanol 0.1 M sodium citrate; pH 4.2. Absorbance 
was quantified at 560 nm using an Infinite M200 (Tecan) microplate reader.   
Tumor xenografts in mice  
POE and SKES cells were resuspended in PBS/matrigel (BD Biosciences, Le Pont de Claix Cedex, 
France) (1:1) and injected (8x106/200µl) subcutaneously in the flanks of six-week old C.B17/SCID 
male and female mice (Charles Rivers Laboratories, France). When tumor volume reached 150 mm3 
(calculated with the formula length×width×depth×0.5432), mice were injected intraperitoneally 
once a day with the indicated dose of PD-173074 (5, 10 or  
20 mg/kg) dissolved in 10% DMSO-90% Corn Oil (Sigma) or placebo in the control group.  Tumor 
growth was monitored with a caliper and mice were sacrificed when tumors reached a volume of 
1500 mm3. Experiments were carried out in accordance with recommendations of the European 
Community (86/609/EEC), the French Competent Authority, the  
UKCCCR guidelines (guidelines for the welfare and use of animals in cancer research), the  
Ethics Committee at ISCIII (CBA #64_2015-v2) and the Spanish Competent Authority  
(PROEX 009/16).  




IHC analyses were done on formalin-fixed, paraffin-embedded xenograft tumors. All tissue samples 
were collected at the Institute of Pathology of the LMU Munich for immediate IHC staining for which 
4-μm sections were cut. Antigen retrieval was carried out by microwave treatment in Dako target 
retrieval solution (S2369). The following primary antibodies were used: polyclonal rabbit anti-
cleaved-caspase-3 (1:100 at room temperature for 60 min; #9661, Cell Signaling) or monoclonal 
rabbit anti-Ki67 (1:200 at room temperature for 60 min; #275R-15 clone SP6, Cell Marque). The 
ImmPRESS Reagent Kit anti-rabbit IgG (MP-7401) was used for antigen detection. Sections were 
counterstained with hematoxylin Gill’s Formula (H-3401, Vector laboratories). The average number 
of positive cells was determined by analysis of 10 high-power fields (HPF, 40x magnification) for each 
xenograft tumor. Statistical differences between groups were calculated with an unpaired tow-
tailed Student’s T-test.   
Patients  
A total of 162 Ewing sarcoma patients with available clinical data and tumor samples were used in 
this study. This cohort consists of 117 Ewing patients for which gene expression profiles in primary 
tumors were analyzed with HG-U133 plus2.0 microarrays (Affymetrix, Santa Clara, CA) (GEO 
accession number GSE34620) and 45 patients whose gene expression profiles were studied with 
Uniset Human 20K I microarrays (Codelink Amersham Bioscience, Piscataway, NJ). All patients 
received a similar protocol treatment.  
Statistical analysis  
For a single comparison of two groups, two-tailed Student’s t test was used and a normal distribution 
was assumed. Variances between the groups that were compared were similar.  
For animal studies, the sample size was estimated to be 6-8 mice considering a signal/noise  
(S/N) ratio of 1.6-1.8, 80% power, assuming a 5% significance level and a two-sided test. No 
investigator blinding was done during the experiment. For in situ studies including overall survival 
and relapse-free survival probabilities, log-rank test was used. For proportions, Fisher’s exact test 




between groups. All statistical calculations were performed using the GraphPad Prism software 
version 6.0 (GraphPad Software, San Diego,  
CA, USA).  
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FIGURE LEGENDS   
  
Figure 1. SPRY1 is negatively regulated by EWS-FLI1 oncoprotein.   
A. Time course of SPRY1, 2, 3 and 4 upon EWS-FLI1 doxycycline-inducible knockdown in 
A673/TR/shEF. EWS-FLI1 expression and two known target genes like LOX and NR0B1 were 
included as controls. mRNA levels were quantified by real time RTqPCR, normalized to that of 
TBP (reference gene) and referred to unstimulated cells. Figure shows data of one out of three 
independent experiments done in triplicate with equivalent results. EWS-FLI1 inhibition in 
A673/TR/shEF cells selectively upregulates  
SPRY1 more than 1,000 times over the rest of members of the SPRY family of genes.  





B. SPRY1 protein is re-expressed upon EWS-FLI1 knockdown in A673/TR/shEF cells. SPRY1 protein 
is undetectable by western blot in A673 cells grown in the absence of doxycycline and thus 
expressing EWS-FLI1. Incubation of A673/TR/shEWSFLI1 cells with doxycycline (1µg/ml, 72 
hours) inhibits EWS-FLI1 expression and dramatically induces re-expression of SPRY1 protein. 
Tubulin was used as a control for loading and transferring.  
C. SPRY1 is undetectable at protein level by western blot in 8 Ewing sarcoma cell lines. Expression 
of the different EWS-ETS proteins is also shown. Tubulin was used as a control for loading and 
transferring.  
D. SPRY1, 2, 3 and 4 mRNA levels in Ewing sarcoma cell lines. Box plot shows absence of SPRY1 
expression in all Ewing sarcoma cell lines tested relative to other members of the SPRY family. 
The figure shows the expression levels normalized to that of TBP  
(reference gene).  
Figure 2. SPRY1 re-expression impairs proliferation in Ewing sarcoma cell lines.  
A. A673/TR, SKES/TR and SKNMC/TR Ewing cell lines expressing constitutively the tetracycline 
repressor (TR) were infected with a doxycycline-inducible lentiviral vector encoding the SPRY1 
cDNA. The figure shows the expression of SPRY1 protein in whole protein extracts isolated from 
A673/TR/SPRY1 (clone 1), SKES/TR/SPRY1  
(clone 7) and SKNMC/TR/SPRY1 (clone 2) cells stimulated with doxycycline (DOX, 1 µg/ml, 72 
hours). High SPRY1 levels were detected in all three cell lines after doxycycline stimulation. EWS-
FLI1 expression was not affected by SPRY1 ectopic expression. The same blot was stripped and 
incubated with anti-tubulin as a control for loading and transferring.   
B. Cell proliferation was assayed in A673/TR/SPRY1, SKES/TR/SPRY1 and SKNMC/TR/SPRY1 cells 




depict the growth curves of the cells cultured in the absence or presence of doxycycline during 
120 h and they show one representative experiment out of three independent experiments 
performed. Re-expression of SPRY1 produces a significant inhibition of cell proliferation. Slight 
artifacts in the graphs at 72 h are a consequence of media change and subsequent readjustment 
of the conditions in the xCELLigence device and do not affect the final result.  
C. A673/TR/SPRY1, SKES/TR/SPRY1 and SKNMC/TR/SPRY1 cells were plated in  
octuplicates and cultured in presence or absence of doxycycline (DOX, 1 µg/ml) for 72 h in 10% 
tetracycline-free fetal bovine serum supplemented media (standard culture conditions). Cell 
proliferation was assayed by BrdU incorporation into DNA. Graphs depict the percentage of cell 
proliferation of doxycycline treated cells (expressing SPRY1) versus control. Figure depicts one 
representative experiment (mean ± SD) out of three independent experiments performed (*** 
P < 0.005).  
D. Cells were platted and cultured as described in C, but kept in 1% fetal bovine serum 
supplemented media (low-serum conditions). Cell proliferation is significantly inhibited in 
doxycycline treated cells (expressing SPRY1) versus control. Figure depicts one representative 
experiment (mean ± SD) out of three independent experiments performed (*** P < 0.005).  
Figure 3. SPRY1 re-expression impairs Ewing sarcoma cell clonogenicity, anchorage 
independent growth, migration and invasion of Ewing sarcoma cells.  
A. A673/TR/SPRY1, SKES/TR/SPRY1 and SKNMC/TR/SPRY1 cells were platted in  
triplicates at low densities and treated with or without doxycycline (DOX, 1 µg/ml) for 9 days. 
Colony formation was measured by crystal violet staining. Pictures show representative wells of 
one out of three independent experiments. Graphs depict a quantification of absorbance 
measured after cell de-staining (one representative experiment out of 3 performed) (mean ± 
SD). Clonogenic growth is significantly impaired in all three cell lines upon SPRY1 re-expression 
(* P < 0.05, ** P < 0.01, *** P < 0.005).  
B. A673/TR/SPRY1, SKES/TR/SPRY1 and SKNMC/TR/SPRY1 cells were platted in triplicate in soft 




subsequently stained with crystal violet. Pictures show representative images of sphere 
formation taken at the end of the experiment. Graphs depict the mean area per particle after 
25 days (mean ± SD). SPRY1 re-expression inhibits sphere formation in all three cell lines (3 
independent experiments) (* P < 0.05, ** P < 0.01, *** P < 0.005).  
C. A673/TR/SPRY1, SKES/TR/SPRY1 and SKNMC/TR/SPRY1 cells were platted in  
triplicates and treated with or without doxycycline (DOX, 1 µg/ml) for 72 h. A “wound gap” was 
created by scratching the cell monolayer using a micropipette tip. Pictures depict the healing of 
the gap as a consequence of cell migration at the beginning, middle and end of the experiments. 
Relative wound closure for each cell line at the end of the experiment is stated in percentages. 
Images show a representative experiment out of three performed.    
D. A673/TR/SPRY1, SKES/TR/SPRY1 and SKNMC/TR/SPRY1 cells were incubated in absence or 
presence of doxycycline (DOX, 1 µg/ml) during 48 h to induce the expression of SPRY1 protein. 
Afterwards, cells were starved for another 24 h. Then they were placed in the upper 
compartment of a transwell and allowed to migrate through the membrane in response to 
serum. Migrating cells were quantified by crystal violet staining. The figure shows the mean ± 
SD of two experiments performed in triplicate. Data are shown as arbitrary units of absorbance 
(abs) (* P < 0.05, *** P <  
0.005).   
Figure 4. SPRY1 inhibits MAPK pathway in Ewing sarcoma cells by inhibiting ERK 
phosphorylation induced by bFGF or serum.  
A673/TR/SPRY1, SKES/TR/SPRY1 and SKNMC/TR/SPRY1 cells were incubated in the absence or in 
the presence of doxycycline (DOX, 1 µg/ml) during 48 h to induce the expression of SPRY1 protein. 
Afterwards, cells were starved for an extra 24 h (1% FBS), and finally stimulated for 15 min with 10% 
FBS or bFGF (bFGF: basic fibroblast growth factor) (10 ng/ml) where indicated. SPRY1, phospho-ERK 
(pERK), ERK and EWS-FLI1 proteins were detected by specific antibodies. Anti-tubulin was used as a 




phosphorylation induced by bFGF or serum in all three cell lines. Graphs depict densitometries 
corresponding to the western blot bands showing pERK/total ERK ratios in percentage versus cells 
cultured in absence of doxycycline (control). The figure shows one representative experiment out 
of 3 performed.   
Figure 5. FGFR-inhibitors block Ewing cell lines proliferation   
A. Four FGFR-inhibitors, namely PD-173074 (PD-74), PD-166866 (PD-66), SU5402  
(SU54) and NVP-BGJ398 (BG-98), inhibit A673, SKNMC, POE, RDES and SKES Ewing cells growth 
in vitro in a dose-dependent manner whereas normal cells (IMR90 fibroblasts) remained 
unaffected. PD-74 proved to be most effective in 4 out of 5 Ewing sarcoma cell lines tested. Cells 
were grown in 10% FBS conditions and cell proliferation was measured after 72 h using a 
Resazurin assay.   
B. PD-173074 (PD-74), PD-166866 (PD-66), SU5402 (SU54) and NVP-BGJ398 (BG-98) impair A673, 
SKNMC and POE Ewing sarcoma cells clonogenic growth in vitro when cells are grown at 5% FBS 
for 10-12 days.   
C. C.B17/SCID mice were injected with POE cells and randomly split in groups. Each group was 
treated intraperitoneally once a day with PD-74 or placebo. The figure shows the evolution of 
tumor volume (mean ± SEM of 6-8 animals per group) versus time. PD-74 treatment significantly 
inhibits tumor growth (P =0.004) of Ewing sarcoma xenografts.  
D. Immunohistochemistry images of tumors obtained in the in vivo experiments. Tissue sections 
were stained with Ki-67 to detect proliferation and cleaved caspase 3 to detect apoptosis. The 
graphs show how PD-74 treatment reduces the number of mitoses (P = 0.001) and increases 
the number of apoptotic cells per field (P = 0.001). Ki-67 staining and graph show a reduction in 




Figure 6. bFGF induces proliferation of Ewing sarcoma cells, which can be antagonized by 
FGFR-inhibition.  
A673/TR/SPRY1, SKES/TR/SPRY1 and SKNMC/TR/SPRY1 cells were incubated in the absence or in 
the presence of doxycycline (DOX, 1 µg/ml) to induce the expression of SPRY1 protein and were 
concomitantly cultured with 1% FBS, bFGF (10 ng/ml), PD173074 (PD-74, 5 µM) or a combination of 
bFGF and PD-74 where indicated. Cell proliferation was measured after 72 h using the Resazurin 
assay. Graphs depict one independent experiment (mean ± SD) out of three performed. SPRY1 re-
expression and PD-74 inhibit cell proliferation induced serum or bFGF treatment (* P <0.05, ** P < 
0.005, ns = non-significant).  
Figure 7. SPRY1 expression is positively correlated with improved overall survival of Ewing 
sarcoma patients.  
A. SPRY1 mRNA expression levels in 24 different solid tumor entities as determined by Affymetrix 
HG-U133plus2.0 DNA microarrays. Data were retrieved from the Gene Expression Omnibus 
(GEO) or the European bioinformatics Institute (EBI) and simultaneously normalized by RMA 
using brain array CDF files (v17, ENTREZG) as previously described 27. Data are represented as 
medians with boxes representing the interquartile range. Whiskers indicate the 10th and 90th 
percentile of the data. The number of analyzed samples is given in parentheses. Ewing sarcoma 
tumors are shown in gray. GIST: gastrointestinal stromal tumor, ATRT: atypical teratoid rhabdoid 
tumor, RMS: rhabdomyosarcoma, NSCLC: non-small cell lung carcinoma, Ca-: carcinoma.   
B. Relative expression of SPRY1 as compared to other EWS-FLI1 target genes (LOX, NR0B1) and 
CD99 in 15 individual Ewing sarcoma cell lines versus 117 primary Ewing sarcoma samples (all 
Affymetrix HG-U133Plus2.0 microarrays). Data were retrieved from the GEO (accession codes: 
GSE8596, GSE36133, GSE70826, and GSE34620) and simultaneously normalized by RMA using 





C. Kaplan-Meier survival estimates (overall survival) in the Ewing sarcoma patient cohort. Patients 
were classified as being either SPRY1-low or -moderate (cut-off: median SPRY1 expression; P = 
0.002, log-rank test).  
D. Graph depicts the relapse-free survival probability versus SPRY1 level of expression (low or 
moderate, cut-off: median SPRY1 expression). SPRY1 expression positively correlates with 
improved relapse-free probability (P = 0.0015, log rank test).  
E. Graph shows the percentage of cases with metastasis at diagnosis versus SPRY1 level of 
expression (low or moderate, cut-off: median SPRY1 expression). Moderate SPRY1 expression 
correlates with lower risk of metastasis at diagnosis (P = 0.002, Fisher’s exact test).  
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